New Driver Mutations Detected in NSCLC.
Researchers have identified additional driver mutations in non-small cell lung cancer that may guide the development of new targeted drugs and immunotherapy. The findings also highlight key differences between two major NSCLC subtypes that could inform future therapeutic strategies.